engleski

Monoisoamyl ester of DMSA reduces 203Hg(NO3)2 retention in rats: 1. Chelation therapy during pregnancy

In this study, efficacy of monoisoamyl meso-2, 3-dimercaptosuccinate (Mi-ADMS) was tested to mobilize mercury in the period of gestation in rats. Its action was compared to meso-2, 3-dimercaptosuccinic acid (DMSA). Pregnant dams (in second third of gestation) received a single intravenous injection of Hg-203(NO3)(2) and oral chelating therapy with DMSA or Mi-ADMS 0.5, 24, and 48 hours after that. Each chelator was administered in three single doses of 0.5 mmol/kg body weight on three consecutive days. The fifth day after Hg-203 exposure, retentions were measured in whole body, organs, and fetuses. Results (expressed as the percentage of Hg-203 dose) showed that all retention values among treated animals were lower than in the control group. Significantly higher reduction of whole body gut, Liver, kidney, and brain retentions in Mi-ADMS (to 2-5% of control values) than in DMSA-treated groups (to 37-80% of control values)was found. Hg-203 retention in uterus, fetuses, and placentae were reduced to 7-8% in Mi-ADMS and to 41-56% of control value in DMSA group. The major routes of Hg-203 excretion after DMSA treatment was urine, whereas fecal excretion was the same as that of controls. After Mi-ADMS treatment, both urinary and fecal Hg-203 excretions were similar to 2-3 times higher than the control values resulting in the lowest body retention.

chelation treatment; DMSA; Mi-ADMS; mercury retention; gestation; rats

nije evidentirano